COWDEN SYNDROME — PTEN

Cowden Syndrome — PTEN loss-of-function producing one of the highest lifetime breast cancer risks of any hereditary syndrome, alongside elevated endometrial, thyroid, colorectal, and kidney cancer risk.

PTEN is on the ACMG SF v3.2 list of genes requiring secondary findings reporting in clinical genome sequencing. Whole genome sequencing characterizes the complete PTEN locus — including promoter region variants and large deletions that standard cancer panels routinely miss.

PTEN

About this condition

Cowden Syndrome — PTEN Hamartoma Tumor Syndrome

Cowden syndrome (CS) — the most common of the PTEN hamartoma tumor syndromes (PHTS) — is an autosomal dominant hereditary cancer predisposition syndrome caused by germline pathogenic variants in PTEN (phosphatase and tensin homolog) on chromosome 10q23.31. PTEN is a tumor suppressor that regulates the PI3K/AKT/mTOR signaling pathway; loss of PTEN function leads to unchecked cellular proliferation and tumor formation. Cowden syndrome is characterized by mucocutaneous lesions (trichilemmomas, papillomatous papules, and acral keratoses), macrocephaly, benign hamartomas in multiple organs, and substantially elevated risks for multiple malignancies. The estimated prevalence is 1 in 200,000, though molecular diagnoses reveal significantly higher frequency.

Lifetime cancer risks in PTEN pathogenic variant carriers are among the highest documented for any hereditary cancer gene: breast cancer risk reaches 67-85% (compared to ~12% population average); endometrial cancer risk approaches 28-44%; thyroid cancer risk (predominantly follicular) reaches 21-38%; colorectal cancer risk is elevated (9-18%); and renal cell carcinoma risk is approximately 34%. Male carriers have elevated breast cancer risk and are also at elevated risk for thyroid and colorectal cancers. Bannayan-Riley-Ruvalcaba syndrome (BRR) and Proteus syndrome (PS) represent allelic PTEN disorders with overlapping but distinct clinical features, all caused by PTEN pathogenic variants.

Approximately 25% of individuals meeting clinical diagnostic criteria for Cowden syndrome do not have an identifiable PTEN coding sequence variant — this group may harbor PTEN promoter region variants, deep intronic variants, large genomic rearrangements, or pathogenic variants in other PHTS-associated genes (SDHB, SDHD, KLLN). NCCN guidelines recommend comprehensive PTEN analysis including deletion/duplication testing as part of complete PHTS evaluation. Management of confirmed PTEN carriers includes annual breast MRI beginning at age 30, annual mammograms beginning at age 30-35, consideration of risk-reducing mastectomy, annual endometrial sampling beginning at age 30-35, and annual thyroid ultrasound.

PTEN hamartoma tumor syndromes include Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome — allelic conditions with overlapping but clinically distinguishable presentations, all caused by PTEN pathogenic variants.

Gene locus: PTEN (10q23.31)

PTEN promoter variants and large genomic rearrangements account for up to 25% of PHTS cases — variants that standard hereditary cancer panels, which sequence only PTEN coding exons, systematically miss.

PTEN promoter region variants are excluded from most cancer panel designs

Germline pathogenic variants in the PTEN promoter region — particularly a recurrent c.-1019_-1018dupTA variant — have been identified in Cowden syndrome patients who test negative on standard PTEN exon-sequencing panels. These variants reduce PTEN transcription, producing functional haploinsufficiency without altering the coding sequence. Standard cancer panels sequence only the 9 PTEN coding exons and canonical splice sites; they do not include the promoter region or intergenic regulatory elements. Whole genome sequencing reads the complete PTEN locus including the promoter, all introns, and the 3' UTR — the regions where regulatory pathogenic variants reside.

Multi-cancer risk management requires confirmed PTEN status at the earliest possible age

PTEN-related cancer risks are among the highest of any hereditary syndrome, and surveillance must begin in the third decade of life — before most breast and endometrial cancers in this population are clinically detectable. NCCN recommends annual breast MRI and mammography from age 30, with endometrial surveillance beginning at 30-35. This aggressive surveillance schedule is justified by the lifetime risk data but requires a confirmed PTEN pathogenic variant to implement. A negative result on an incomplete panel — one that did not evaluate the PTEN promoter or structural rearrangements — may be providing false reassurance that delays necessary surveillance by years.

Cowden Syndrome — PTEN loss-of-function producing one of the highest lifetime breast cancer risks of any hereditary syndrome, alongside elevated endometrial, thyroid, colorectal, and kidney cancer risk.

Cowden Syndrome — PTEN Hamartoma Tumor Syndrome

PTEN promoter variants and large genomic rearrangements account for up to 25% of PHTS cases — variants that standard hereditary cancer panels, which sequence only PTEN coding exons, systematically miss.

PTEN promoter region variants are excluded from most cancer panel designs

Multi-cancer risk management requires confirmed PTEN status at the earliest possible age

Others in Hereditary Cancer

One test. A lifetime of answers.